Sex: M
Vaccine: COVID19
Symptoms: Abscess, Activated partial thromboplastin time, Alanine aminotransferase, Aspartate aminotransferase, Basophil count
Clinical narrative: HEART ATTACK; GROGGY; ABSCESS; This spontaneous report received from a patient via other manufacturer (Company) concerned a 56 year old male. The patient's weight was 244 pounds, and height was 71 inches.  The patient's past medical history included: chest pain, possible unstable angina, three distinct episodes of chest pressure, discomfort, weakness, shortness on breath, peripheral edema, hand eczema, laproscopic cholectectomy, left knee surgery, percutaneous transluminal angioplasty, and colonoscopy, and concurrent conditions included: non alcohol user, dyslipidemia, occlusion of the left anterior descending coronary artery, coronary artery disease, sulfa allergy (BACTRIM), penicillin allergy manifested by angioedema, ex-cigarette smoker (stopped on FEB-2022), chronic plaque psoriasis, and psoriasis, and other pre-existing medical conditions included: The patient abstained from recreational drugs. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number was not reported) dose was not reported, 1 total, start therapy date was not reported for prophylactic vaccination.  The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.  Non-company suspect drug included: risankizumab (solution for injection, subcutaneous, batch number was not reported) 75 mg, 1 time every 3 - 2 (unspecified unit) from JUL-2021 for chronic plaque psoriasis.  Concomitant medications included acetylsalicylic acid, amlodipine, atorvastatin, clopidogrel, famotidine, glyceryl trinitrate, ibuprofen, and losartan used for unknown indication.  On an unspecified date, the patient experienced groggy, and abscess after getting covid-19 vaccine/ covid vaccine reaction. On 14-FEB-2022, the patient experienced heart attack. On an unspecified date, the patient was hospitalized. Number of days of hospitalization was not reported. On 21-FEB-2022, Laboratory data included: Alanine aminotransferase 33 UNITS/L, Albumin (NR: not provided) 4.8 g/dL, Alkaline phosphatase 81 UNITS/L, Aspartate aminotransferase 27 UNITS/L, BNP (NR: not provided) 30 pg/mL, Basophil count 500 /MCL, Basophils (NR: not provided) 0.6 %, Bilirubin total (NR: not provided) 0.5 mg/dL, Blood protein / albumin (NR: not provided) 7.6 g/mL, Blood urea nitrogen (NR: not provided) 13 mg/dL, Body surface area (NR: not provided) 2.36 m2, CO2 1144, Calcium (NR: not provided) 9.5 mg/dL, Chloride (NR: not provided) 103 mmol/L, Creatinine (NR: not provided) 0.80 mg/dL, Creatinine clearance (NR: not provided) 97.61 mL/min, Diastolic blood pressure (NR: not provided) 74 mmHg, Eosinophils 8000 /MCL, Eosinophils (NR: not provided) 9.1 %, Estimated glomerular filtration rate 81 UNITS/L2, MORE THAN 60 NA, Estimated glomerular filtration rate 81 UNITS/L2, MORE THAN 60 NA, Glucose (NR: not provided) 77 mg/dL, Haemoglobin (NR: not provided) 14 g/dL, Hematocrit (NR: not provided) 42.5 %, Lymphocytes 2000 /MCL, Lymphocytes (NR: not provided) 22.8 %, MCHC (NR: not provided) 30 pg, Mean corpuscular volume 91, Mean platelet volume (NR: not provided) 10.7 fL, Monocyte count 70000 /MCL, Monocyte count (NR: not provided) 7.7 %, Neutrophil count 51000 /mcl, Neutrophil count (NR: not provided) 59.8 %, Platelet count 305 k/mol, Potassium (NR: not provided) 3.7 mmol/L, Pulse rate (NR: not provided) 68 {beats}/min, Red blood cell count 35.97, Red cell distribution width (NR: not provided) 13.9 %, Systolic blood pressure (NR: not provided) 130 mmHg, Troponin 27 UNITS/L5, WBC 27 UNITS/L6, and Weight 27 UNITS/L9.  On 22-FEB-2022, Laboratory data included: APTT 35.5, Blood urea nitrogen 14, Body mass index (NR: not provided) 34.19 kg/m2, Body temperature 36.5 Degrees C, Calcium 1141, Carbon dioxide 1145, Chloride 108, Creatinine 0.85, Creatinine clearance (NR: not provided) 109.81 mL/min, Diastolic blood pressure (NR: not provided) 88 mmHg, Eosinophils 81 UNITS/L7, Glucose 33 UNITS/L1, Heart rate (NR: not provided) 55 {beats}/min, Hematocrit 33 UNITS/L5, Hemoglobin 321, Lymphocytes 17.2, Monocyte count 6.6, Neutrophil count 35.90, Oxygen saturation (NR: not provided) 98 %, Platelet count 35.94, Potassium 4.3, Systolic blood pressure (NR: not provided) 143 mmHg, and WBC 27 UNITS/L7.  On 23-FEB-2022, Laboratory data included: APTT 35.9, Alkaline phosphatase 114, Aspartate aminotransferase 20, Bilirubin total 0.5, Blood urea nitrogen 15, CO2 1146, Calcium 9.4, Chloride 108, Cholesterol 180, Creatinine 1147, Eosinophils 10.3, Glucose 33 UNITS/L2, HDL 33 UNITS/L7, Hematocrit 33 UNITS/L6, Hemoglobin 320, INR 0.97, LDL 323, Lymphocytes 327, Monocyte count 7.6, Neutrophil count 60.7, Platelet count 35.95, Potassium 4.5, Protein 6.5, 11.7, Protein 6.5, 11.7, Sodium 27 UNITS/L1, Triglycerides 27 UNITS/L4, and WBC 27 UNITS/L8.  Laboratory data (dates unspecified) included: Alanine aminotransferase 32, Electrocardiogram: heart attack, and Non-high-density lipoprotein cholesterol 148. The action taken with covid-19 vaccine ad26.cov2.s was not applicable; and dose of risankizumab was not changed. The patient recovered from heart attack on 23-FEB-2022 and from abscess on an unspecified date, and had not recovered from groggy. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0:20220617736-covid-19 vaccine ad26.cov2.s-Heart attack. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: MEDICAL HISTORY(  chest pain, possible unstable angina, three distinct episodes of chest pressure, percutaneous transluminal angioplasty) and concurrent conditions  dyslipidemia, occlusion of the left anterior descending coronary artery, coronary artery disease, ex-cigarette smoker stopped on FEB-2022). Therefore, this event(s) is considered not related.